All In Biotech

Drug Trial Radar · NCT07455851

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

A FIH Phase 1/2 Study to Assess Safety, Tolerability, and Preliminary Anti-Tumor Activity of REGN17372, an Anti-GPRC5D x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Linvoseltamab, an Anti-BCMA x Anti-CD3 Bispecific Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Mar 26, 2026

Primary completion

Sep 30, 2033

Study completion Sep 30, 2033

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Mar 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching a drug called REGN17372 used with another drug called linvoseltamab (each individually called "study drug" or "study drugs" when combined) in participants with relapsed (when a tumor comes back) or refractory (when a tumor does not respond to treatment) multiple myeloma. This study is the first time REGN17372 will be given to humans. The aim of the study is to understand if REGN17372 can be given safely with linvoseltamab, and if so, what dosing regimen should be used for this treatment combination, in comparison with linvoseltamab alone. The study is looking at: * What side effects may happen from taking REGN17372 with linvoseltamab * How well REGN17372 and linvoseltamab, or linvoseltamab alone, work in treating multiple myeloma * What is the best dose of REGN17372 when given with linvoseltamab * How much study drug(s) are in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the study drugs less effective or could lead to side effects) * If and how REGN17372 and linvoseltamab affect the overall quality of life, daily activities, symptoms and treatment side effects based on participant own feedback (Phase 2)

Conditions

  • Relapsed Refractory Multiple Myeloma (RRMM)

Interventions

  • LinvoseltamabDrug

    Administered per protocol

  • REGN17372+LinvoseltamabDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Dose Limiting Toxicities (DLTs) from the first dose of REGN17372 in combination with linvoseltamabTime frame: Up to 35 days
  2. Occurrence of Treatment Emergent Adverse Events (TEAEs) associated with REGN17372 in combination with linvoseltamabTime frame: Up to 5 years
  3. Severity of TEAEs associated with REGN17372 in combination with linvoseltamabTime frame: Up to 5 years
  4. Very Good Partial Response (VGPR) or better as determined by the investigator using the International Myeloma Working Group (IMWG) response criteria in patients receiving combination study drugsTime frame: Within 12 weeks of starting cycle 1
  5. VGPR or better as determined by the investigator using the IMWG response criteria in patients receiving Linvoseltamab monotherapyTime frame: Within 12 weeks of starting cycle 1
  6. Partial Response (PR) or better as determined by the investigator using the IMWG response criteria in patients receiving combination study drugsTime frame: Within 12 weeks of starting cycle 1
  7. PR or better as determined by the investigator using the IMWG response criteria in patients receiving Linvoseltamab monotherapyTime frame: Within 12 weeks of starting cycle 1

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • South Western Sydney Local Health District - Liverpool Hosptial

    Liverpool, New South Wales, Australia · Recruiting

  • Prince of Wales Hospital

    Randwick, New South Wales, Australia · Recruiting

  • Illawarra Cancer care centre, Wollongong Hospital

    Wollongong, New South Wales, Australia · Recruiting

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia · Recruiting

  • St Vincents Hospital Melbourne

    Fitzroy, Victoria, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Evangelismos General Hospital

    Athens, Attica, Greece · Recruiting

  • 1st Health Region of Athens, Alexandra General Hospital of Athens

    Athens, Attica, Greece · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.